Navigation Links
Cancer vaccines -- Taking a jab at cancer by stimulating the immune system

As the first FDA-approved cancer vaccine, designed to protect against human papillomavirus, has moved from scientific discussion to social debate, other vaccine studies are continuing to make progress. While HPV vaccine efforts had the "benefit" of a viral source for the disease, other researchers are developing vaccines for cancers that are not virally based, in an effort to coax the immune system into attacking cancerous cells. Today at the 2007 Annual Meeting of the American Association for Cancer Research, presentations on ongoing HPV trials and other new approaches to stimulating the immune system are injecting momentum into cancer vaccine research.

Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine: Abstract 4900

Ongoing evaluation of a phase II trial of a human papillomavirus vaccine, developed to prevent cervical cancer, shows that the vaccine continues to protect against HPV types 16 and 18 at five and a half years into the study, according to researchers from the University of Louisville. Their findings also show that the vaccine offers significant cross-protection for HPV types 45 and 31.

The study follows 1113 women between the ages of 15 and 25 in North America and Brazil randomized to receive three doses of either the vaccine or the control. The vaccine, made by GlaxoSmithKline, which funded the study, is designed to protect against two strains of HPV, types 16 and 18, which together are thought to cause nearly 72 percent of all cases of cervical cancer.

At over five years into the study’s follow-up, the researchers found that approximately 98 percent of subjects still maintained protection against HPV types 16 and 18. Regardless of HPV status, the vaccine also appears to prevent most occurrences of cervical intraepithelial neoplasia lesions ?abnormal, precancerous cell growths found in the cervix.


'"/>

Source:American Association for Cancer Research


Page: 1 2 3 4 5

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Jump-starting T Cells In Skin Cancer
3. Deficient DNA Repair Capacity Associated With Increased Risk Of Breast Cancer
4. Fox Chase Cancer Center scientists identify immune-system mutation
5. Breakthrough Microarray-based Technology for the Study of Cancer
6. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
7. Fundamental Finding Yields Insight into Stem Cells, Cancer; Opens Door to Drug Discovery
8. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
9. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
10. New Breast Cancer Test Could Save Lives
11. Estrogen-like Component of Plastic Stimulates Growth of Certain Prostate Cancer Cells
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cancer vaccines Taking jab cancer stimulating the immune system

(Date:2/10/2015)... WALTHAM, Mass., Feb. 10, 2015  Alere Inc. ... announced its financial results for the quarter ended ... Executive Officer and President of Alere said, "We ... refocussing Alere as the global leader in rapid ... closing the Alere Health divestiture in early January ...
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... corporate website ( http://www.nxt-id.com/ ) as part of its ... wallet. The Company launched its new consumer website for ... Pereira , CEO of NXT-ID said, "Our new corporate ...
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying to ... and potential for genomic science as a means to ... prevention and treatment.  I was honored to participate in ... precision medicine program. Since the 1980s ... of genomics—from the first sequenced genome of a free ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... DCResearchers at the Center for Neuroscience Research ... two major types of signaling pathways activated during brain ... Notch pathwayoperate together to determine how many and which ... repair in developing and adult brains. This knowledge may ...
... Cancer Epidemiology (LACE) study, 1,897 participants diagnosed with early-stage ... average 2 years post-breast cancer diagnosis were evaluated for ... and death. The women, who were generally light ... The study reported an increase in risk of ...
... there,s a new reason to grab a glass of milk when ... American Journal of Clinical Nutrition . In a 2-year weight loss ... milk. Israeli researchers found that adults who drank the most milk ... levels at 6 months, lost more weight after 2 years than ...
Cached Biology News:Discovery of key pathway interaction may lead to therapies that aid brain growth and repair 2New study finds milk drinkers may have a healthy weight advantage 2
(Date:3/6/2015)... 06, 2015 Global Specimen Solutions, ... focused on specimen management and informatics, announced today ... Specimen Solutions, Inc. is excited to catapult our ... that will further enhance our proprietary informatics tools ... specimen research. GSS has proved rapid market uptake ...
(Date:3/6/2015)... 6, 2015   Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel flavor ... that John Poyhonen , the Company,s President and ... Vice President and Chief Financial Officer, will present an ... Wednesday, March 11, at 2:00 p.m. Eastern Time (11:00 ...
(Date:3/6/2015)... 2015 Anton Paar has released an ... utilizing laboratory refractometers. Sodium hydroxide (NaOH, also known ... a variety of products including pretzels, colored fabrics, soap ... of the chemical industry; its applications range from the ... everything in between. NaOH is used in the ...
(Date:3/6/2015)... Die SARAH-Studie ... Assistance Publique - Hôpitaux de ... französische, gemeinschaftliche, randomisierte Kontrollstudie für die mehr ... werden Patienten mit fortgeschrittenem hepatozellulärem Karzinom (HCC), ... behandelt wurden. Die Ergebnisse werden für Ende ...
Breaking Biology Technology:Global Specimen Solutions, Inc. Closes Series A Funding 2Global Specimen Solutions, Inc. Closes Series A Funding 3SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE THE 27TH ANNUAL ROTH CONFERENCE 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6
... 2009) will feature OpenClinica in a special workshop titled "Open Source ... ... Porto, Portugal (PRWEB) January 8, 2009 -- OpenClinica will be ... Health Informatics (HEALTHINF 2009) January 14-17, 2009 in Porto, Portugal. The ...
... January 7, 2008 Researchers from Harvard University and ... first time, a repulsive quantum mechanical force that could be ... applications. , The study, led by Federico Capasso, Robert L. ... and Applied Science (SEAS), will be published as the January ...
... 7 Amgen (Nasdaq: AMGN ) will present ... 9:00 a.m. Pacific Time on Monday, Jan. 12, 2009, at ... Chairman and CEO Kevin Sharer will present at the conference. ... Internet and can be accessed from Amgen,s Web site, ...
Cached Biology Technology:OpenClinica to Present at International Conference on Health Informatics, January 14-17, Porto, Portugal 2Researchers measure elusive repulsive force from quantum fluctuations 2
... >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long been ... radiolabeled ligands selected to keep pace with ... of products and services for receptor research ... radioligands. If you do not find exactly ...
... Fluorescence Test Plate consists of an anodized ... Inert Organic Fluorescent Compounds embedded in polymerized ... on BioTeks FLx800 and Synergy Multi-Detection Readers. ... GLP compliance while reducing the need for ...
... Software reads and processes raw ... microarray data for analysis. ... one 2-year license for Feature ... , * one CD-ROM ...
... Gel Stain combo offers these benefits: ... separately Offers a safer ... Eliminates risks to yourself, the environment and ... 100 bp to >30 kb. UltraPure Agarose is a ...
Biology Products: